MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on December 13, 2006; DOI: 10.1124/mol.105.021683


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.021683v1
71/3/713    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wadkins, R. M
Right arrow Articles by Potter, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wadkins, R. M
Right arrow Articles by Potter, P. M.


Received for publication December 15, 2005.
Revised December 12, 2006.
Accepted for publication December 12, 2006.

Analysis of mammalian carboxylesterase inhibition by trifluoromethylketone-containing compounds

Randy M Wadkins 1, Janice L Hyatt 2, Carol C Edwards 2, Lyudmila Tsurkan 2, Matthew R Redinbo 3, Craig E Wheelock 4, Paul D Jones 5, Bruce D Hammock 5, Philip M. Potter 2*

1 University of Mississippi 2 St. Jude Children's Research Hospital 3 University of North Carolina 4 Karolinska Institute 5 University of California Davis

* Address correspondence to: E-mail: phil.potter{at}stjude.org

Abstract

Carboxylesterases (CE) are ubiquitous enzymes that hydrolyze numerous ester-containing xenobiotics including complex molecules such as the anticancer drugs, CPT-11 and capecitabine, and the pyrethroid insecticides. Due to the role of CEs in the metabolism of many exogenous and endogenous ester-containing compounds, a number of studies have examined the inhibition of this class of enzymes. Trifluoromethylketone-containing (TFK) compounds have been identified as potent CE inhibitors. In this article, we present inhibition constants for 21 compounds, including a series of sulfanyl, sulfinyl and sulfonyl TFKs with 3 mammalian CEs, as well as human acetyl- and butyrylcholinesterase. In order to examine the nature of the slow tight-binding inhibitor/enzyme interaction, assays were performed using either a 5 min or a 24 hour preincubation period. Results showed that the length of the preincubation interval significantly affects the inhibition constants on a structurally-dependent basis. The TFK-containing compounds were generally potent inhibitors of mammalian CEs, with Ki values as low as 0.3 nM observed. In most cases, thioether-containing compounds were more potent inhibitors then their sulfinyl or sulfonyl analogs. QSAR analyses demonstrated excellent observed versus predicted values correlations (r2 ranging from 0.908 - 0.948) with cross correlation coefficients (q2) of ~0.9. In addition, pseudoreceptor models for the TKF analogs were very similar to structures and models previously obtained using benzil- or sulfonamide-based CE inhibitors. These studies indicate that more potent, selective CE inhibitors, containing long alkyl or aromatic groups attached to the thioether chemotype in TFKs, can be developed for use in in vivo enzyme inhibition.


Key words: Structure-activity relationships and modeling, Carboxylesterase, Structure/function/mechanism





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics